Form 4: Cingulate Director Werth Boosts Stake in Private Placement

Cingulate Inc. Director and 10% owner Peter J. Werth acquired additional common stock and warrants through a private placement.

Summary

• Peter J. Werth, a Director and 10% Owner of Cingulate Inc. (CING), acquired additional securities on February 6, 2026.
• The acquisition included 19,455 shares of Common Stock at a price of $5.04 per share.
• Additionally, 15,564 Warrants to purchase Common Stock were acquired at an implied price of $0.1 per warrant, with an exercise price of $5.04 per share.
• These securities were obtained as part of a private placement, which was previously disclosed in a Current Report on Form 8-K filed with the SEC on January 28, 2026.
• The acquisitions were made indirectly through Werth Family Investment Associates LLC.
• Following these transactions, Werth Family Investment Associates LLC beneficially owns 117,449 shares of Common Stock and 15,564 Warrants.
• Peter J. Werth directly owns 92 shares of Common Stock.
• The warrants are exercisable upon Cingulate Inc. obtaining stockholder approval of the private placement, as required by Nasdaq rules, and will expire 36 months after their exercise date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant insider's increased stake often signals confidence in the company's future, though the capital raise itself might dilute existing shareholders.

Positives

• A Director and 10% owner, Peter J. Werth, increased his beneficial ownership in Cingulate Inc., signaling confidence in the company's future prospects.
• The acquisition was part of a private placement, which typically involves sophisticated investors and can provide capital to the company.

Risks

• The exercisability of the acquired warrants is contingent upon Cingulate Inc. obtaining stockholder approval of the private placement, as mandated by Nasdaq rules.

Future Outlook

The warrants acquired by Peter J. Werth will become exercisable upon Cingulate Inc. securing stockholder approval for the private placement, a requirement under Nasdaq rules. The warrants will expire 36 months after their exercise date.

Industry Context

StockSavvy.ai notes that insider purchases, especially by significant shareholders and directors, are often interpreted by the market as a positive signal, indicating management's belief in the company's future prospects. This private placement suggests Cingulate is raising capital, which is common for development-stage biotech or pharmaceutical companies.

Comparison to Industry Standards

• Insider buying by a director and 10% owner, such as Peter J. Werth, is generally viewed as a strong vote of confidence, aligning with similar signals observed in other small-cap biotechnology firms where management's personal investment often precedes significant milestones or positive developments.

Related Party Transactions

• Peter J. Werth, a Director and 10% owner, acquired securities from Cingulate Inc. as part of a private placement.
• The acquisition was made indirectly through Werth Family Investment Associates LLC.

Stakeholder Impact

• Shareholders: Potential dilution from the private placement and future warrant exercise, but also a positive signal from insider buying.
• Company: Influx of capital from the private placement.

Next Steps

• Cingulate Inc. needs to obtain stockholder approval for the private placement to allow the warrants to become exercisable.

Key Dates

Recommendation

A director and 10% owner increasing their stake through a private placement suggests confidence in the company's future, which is generally a positive indicator. However, without broader financial context from a full earnings report or strategic update, a 'hold' recommendation is prudent, acknowledging the positive insider signal while awaiting more comprehensive data.

Keywords

Cingulate, CING, Peter Werth, insider trading, Form 4, private placement, common stock, warrants, director, beneficial ownership